CST Pharma Ltd: UK Public Sector Contracts Won & Awards
Companies House: Private Limited Company·Walsall·Nationwide (UK)·Main market: Pharmaceutical products
Official UK PPONPBDW-5911-ZDBQCompanies House04212740 ↗ · Active
Where they wini
i
73 awards (71 for a named lot, 97%, 2 for a whole procedure with no lot named) · top CPV classes, shares of all 73 awards. An award may cover more than one class.
3360 Pharmaceutical products72 awards · 99% · 70 awards naming a lot + 2 whole-procedure awards3369 Various medicinal products1 award · 1% · awards naming a loti
i
Where their buyers arei
i
ITL1 region of the buyer office · known for 57 of 57 awarded procedures · each procedure counts once
Bidding recordi
i
Procurement Act 2023 award notices name every bidder · 8 notices name this supplier since 20 Aug 2025 · observed bids, not an estimate
i
i
i
| Notice | Authority | Outcome | Bidders | Published |
|---|---|---|---|---|
| NHS National Generic Pharmaceuticals - Wave 16a | NHS England | appointed | 125 | 9 Oct 2026 |
| NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026 | NHS England | appointed | 25 | 21 Jul 2026 |
| NHS National Generics Pharmaceuticals - Supply Chain Resilience | NHS England | not appointed | 41 | 6 Jul 2026 |
| NHS National Branded Interim - 1 June 2026 | NHS England | appointed | 53 | 22 May 2026 |
| NHS National Generic Pharmaceuticals - Wave 15c | NHS England | appointed | 118 | 26 Feb 2026 |
| NHS National Proprietary Pharmaceuticals - Low Molecular Weight Heparins and Fondaparinux Products | NHS England | not appointed | 11 | 18 Dec 2025 |
| NHS National Framework for Transition products (Axitinib and Eltrombopag) | NHS England | not appointed | 15 | 4 Sept 2025 |
| NHS National Framework for Transition products (Nilotinib and Ticagrelor) | NHS England | appointed | 17 | 20 Aug 2025 |
Bidder names come from Procurement Act 2023 award notices, which list every bidder (from 2025). Older notices name no bidders, so earlier contests do not appear here. Latest ten notices shown.
Who they sell toi
i
Authorities named on this supplier’s published awards · ranked by distinct procedures · a framework or DPS adds one award record per appointed supplier
i
NHS & health96%(70 awards)
70 of 73 awards are NHS & health (96%).Type not classified4%(3 awards)
3 of 73 awards are Type not classified (4%).
| Authority | Procedures | Share | Award records | Last activity |
|---|---|---|---|---|
| NHS England | 21 | 36.8% | 32 | 27 Aug 2026 |
| The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") | 17 | 29.8% | 23 | 27 Jul 2026 |
| NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) | 9 | 15.8% | 9 | 17 Sept 2026 |
| The NHS Commissioning Board (operating under the name of NHS England) | 5 | 8.8% | 6 | 7 Feb 2022 |
| Department of Health & Social Care | 2 | 3.5% | 2 | 11 Nov 2020 |
| University Hospitals of Derby and Burton NHS Foundation Trust | 2 | 3.5% | 2 | 3 Jan 2024 |
| eTenderwales | 1 | 1.8% | 1 | 17 Jun 2025 |
Share = of the 57 procedures with an award naming this supplier. Last activity = award date, or notice publication when no award date was published.
Contracts endingi
i
65 of 75 awards carry an end date, 23 estimated from the duration · not a retender forecast
| Contract | Ends | Published value |
|---|---|---|
| Range of Generic Cancer Medicines (single supplier) | 3 Jan 2027 estimated | £3,432,063 ceiling |
| Generic Drugs - Tablets & Capsules | 31 Jan 2027 | £43,648 |
| Generic Anti-Infective Drugs | 31 Jan 2027 | £196,426 |
| Wave 15a - Hospital Only Products (DNW & DLN regions) | 31 Jan 2027 | £1 ceiling |
| NHS National Framework for Transition products (Nilotinib and Ticagrelor) | 31 Jan 2027 | £22,097,000 ceiling |
| Wave 14c - Orals (plus non-parenteral) Products (all regions) | 31 May 2027 | £1 ceiling |
| Wave 15a - Orals (plus non-parenteral) Products (all regions) | 31 May 2027 | £1 ceiling |
| All Other Presentations | 21 Jun 2027 estimated | £28,861,104 ceiling |
| ENT, Ophthalmology & Skin Generic Medicines/Medical Devices | 7 Aug 2027 estimated | £9,647,464 ceiling |
| Wave 15b - Hospital Only DCE & DSW regions | 30 Sept 2027 | £1 ceiling |
Soonest 10 of 15.
Recent awards
Latest 30 of 73 award records naming this supplier
Contracts Finder adds 2 more procedures won by this supplier, mostly below the Find a Tender threshold or from before 2025. Each is counted once beside any Find a Tender copy; they are in the totals, not in this list.
About this data
- One profile per supplier. Built from award and contract notices that name this supplier; different spellings and registration numbers of the same company are merged into this profile.
- Values are published values. The table mirrors what the notice published: framework ceilings and joint awards are labelled and never counted as this supplier's money, and † marks a value taken from the contract notice when the award published none. Only awards made to this supplier alone count towards its value, excluding VAT. It is not turnover.
- Regions in the buyer chart describe the buyer office, not where the work is delivered or the supplier’s registered address.
- Contract end dates. Published on 42 of 75 awards, estimated from the published duration on 23 more (marked “estimated”); those feed “Contracts ending”. Published values in that list come from either source; Contracts Finder figures are shown as published and stay out of this profile’s money totals.
- Source. Official UK public procurement notices (Find a Tender, Contracts Finder and Public Contracts Scotland), reused under the Open Government Licence v3.0, updated through the day and rebuilt nightly. Not every figure uses every feed, and each one shows how many records it rests on: see the methodology. Spotted something wrong? Tell us.